Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

This randomized, open-label trial compared the efficacy and safety of adjuvant nab-paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430). METHODS: We assigned 866 treatment-naive patients with pancreatic ductal a...

Descripción completa

Detalles Bibliográficos
Autores principales: Tempero, Margaret A., Pelzer, Uwe, O'Reilly, Eileen M., Winter, Jordan, Oh, Do-Youn, Li, Chung-Pin, Tortora, Giampaolo, Chang, Heung-Moon, Lopez, Charles D., Bekaii-Saab, Tanios, Ko, Andrew H., Santoro, Armando, Park, Joon Oh, Noel, Marcus S., Frassineti, Giovanni Luca, Shan, Yan-Shen, Dean, Andrew, Riess, Hanno, Van Cutsem, Eric, Berlin, Jordan, Philip, Philip, Moore, Malcolm, Goldstein, David, Tabernero, Josep, Li, Mingyu, Ferrara, Stefano, Le Bruchec, Yvan, Zhang, George, Lu, Brian, Biankin, Andrew V., Reni, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2023
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082313/
https://www.ncbi.nlm.nih.gov/pubmed/36521097
http://dx.doi.org/10.1200/JCO.22.01134

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10082313/
https://www.ncbi.nlm.nih.gov/pubmed/36521097
http://dx.doi.org/10.1200/JCO.22.01134

Ejemplares similares